5245182026-06-265245182026-06-262026-06-265245182026-06-262026-06-26AmalgamatedEntityDomain15245182026-06-26AmalgamatedEntityDomain15245182026-06-262026-06-26AmalgamatedEntityDomain25245182026-06-26AmalgamatedEntityDomain2xbrli:purexbrli:shares524518KREBS BIOCHEMICALS AND INDUSTRIES LIMITEDKREBSBIONAINE268B01013NewAmalgamation/ Mergertrue2026-06-2613:00:002026-06-26Krebs Biochemicals & Industries LimitedTransferorListed Entity (self)Manufacturing ./ marketing of bulk drugs156841340.727458764520.27260021560586100000000Ipca Laboratories LimitedTransfereeOthersAssociate Company/ Promoter CompanyTrans-national pharmaceuticals Company with a standalone income of Rs. 7431 crores, manufcaturing and marketing pharmaceuticals1134674720.44721402367460.55280025370421811134674720.44661406166850.5534002540841571true2026-06-262026-06-26falsetrueThe Transferee Company holds 49.65% of the voting capital of the CompanytrueManufacturing and Marketing of Pharmaceuticalsa. The Amalgamation / merger of Transferor/Amalgamating Company into the Transferee/Amalgamated Company will result in operational synergies resulting in cost optimization. b. The merger would result in consolidation of business of the Amalgamating Company with the business of the Amalgamated Company thereby resulting in an increased business of the combined entity. c. Reduction of administrative responsibilities, multiplicity of records and statutory, legal and regulatory compliances. d. The Amalgamating Company has the capability and manufacturing facility to manufacture the fermentation based Active Pharmaceutical Ingredients (APIs) which capability and facility the Amalgamated Company does not have. Thus, the Scheme will enable the Amalgamated Company to Research, develop and commercialize new fermentation based APIs and increase its business. e. The Amalgamating Company produces one of the fermentation based API which is used as a therapeutic ingredient in the largest selling formulation of the Amalgamated Company. There are only a handful manufacturers of this API in the world. The Scheme will secure the uninterrupted supply of this API to the Amalgamated Company. f. The Amalgamating Company produces few drug intermediates that are used by the Amalgamated Company in manufacturing of their key Active Pharmaceutical Ingredients (APIs). The Scheme will secure the uninterrupted supply of these drug intermediates to the Amalgamated Company. g. The Amalgamating Company is continuously incurring losses and is unable to spend on research and development for development of new fermentation based APIs so as to optimally utilize its manufacturing capabilities and increase its business. The Scheme, with financial strength, technical and marketing capabilities of the Amalgamated Company will facilitate this.Shares07:200Share Consideration RatioNot applicable since upon merger, the Company would get merged with Ipca Laboratories Limited i.e. the Transferee CompanyNone